PTGXProtagonist Therapeutics, Inc.
Is it safe?
Nothing alarming, nothing pristine: insiders quiet and big price swings.
Insiders were net sellers (-$41.4M, 90 days to Oct 8, 2026), selling is often routine.
Large price swings, high volatility. Worst drawdown -86% · now 9% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can PTGX take a bad year?
The deepest fall in PTGX's price history on file is −86%; it is 9.4% below its high today.
Worst drawdown on file · −9.4% today
- Annualised volatility
- 57%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Cash and short-term investments
- $783M
- EBITDA, trailing twelve months
- $60M
- Operating profit, trailing twelve months
- $58M
- Annualised volatilitytwo years of daily moves
- 57%
- Worst drawdown on file
- −86%
- Below its 52-week high
- 9.4%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.